Pinatuzumab is a humanised monoclonal antibody targeting CD22, commonly used to synthesise the ADC molecule Pinatuzumab vedotin, which is employed in the study of B-cell malignancies such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL).
Purity:
95.00%
CAS Number:
[1639820-81-7]
Target:
Integrin|||Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted
